{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:48:03Z","timestamp":1785206883101,"version":"3.55.0"},"reference-count":74,"publisher":"Japan Endocrine Society","issue":"3","funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1041"],"award-info":[{"award-number":["23FC1041"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16406"],"award-info":[{"award-number":["22K16406"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0466","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T22:10:35Z","timestamp":1731363035000},"page":"243-257","source":"Crossref","is-referenced-by-count":5,"title":["Updates on WHO 5th edition classification, molecular characteristics and tumor microenvironment of adrenocortical carcinomas"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-2632","authenticated-orcid":false,"given":"Yuto","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Tohoku University Hospital, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikiyo","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Tohoku University Hospital, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Sasano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Volante M, Buttigliero C, Greco E, Berruti A, Papotti M (2008) Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol 61: 787\u2013793.","DOI":"10.1136\/jcp.2007.050625"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, et al. (2023) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 189: G1\u2013G42.","DOI":"10.1093\/ejendo\/lvad066"},{"key":"3","unstructured":"3 WHO classification, 5<sup>th<\/sup> edition, Endocrine and Neuroendocrine tumours, IARC. https:\/\/tumourclassification.iarc.who.int\/home accessed on September 30, 2024."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Sasano H, Suzuki T, Nagura H, Nishikawa T (1993) Steroidogenesis in human adrenocortical carcinoma: biochemical activities, immunohistochemistry, and <i>in situ<\/i> hybridization of steroidogenic enzymes and histopathologic study in nine cases. Hum Pathol 24: 397\u2013404.","DOI":"10.1016\/0046-8177(93)90088-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Abiven G, Coste J, Groussin L, Anract P, Tissier F, et al. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91: 2650\u20132655.","DOI":"10.1210\/jc.2005-2730"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Ishikawa Y, Yamazaki Y, Tezuka Y, Omata K, Ono Y, et al. (2024) Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: possible effects of <i>in situ<\/i> disorganized glucocorticoid production on tumor immunity. J Steroid Biochem Mol Biol 238: 106462.","DOI":"10.1016\/j.jsbmb.2024.106462"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Lippert J, Dischinger U, Appenzeller S, Prete A, Kircher S, et al. (2023) Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study. Eur J Endocrinol 189: 262\u2013270.","DOI":"10.1093\/ejendo\/lvad112"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Weiss LM (1984) Comparative histopathologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8: 163\u2013169.","DOI":"10.1097\/00000478-198403000-00001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Papotti M, Lib\u00e8 R, Duregon E, Volante M, Bertherat J, et al. (2011) The Weiss score and beyond\u2014histopathology for adrenocortical carcinoma. Horm Cancer 2: 333\u2013340.","DOI":"10.1007\/s12672-011-0088-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Aubert S, Wacrenier A, Leroy X, Devos P, Carneille B, et al. (2002) Weiss system revisited a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26: 1612\u20131619.","DOI":"10.1097\/00000478-200212000-00009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, et al. (2009) Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 55: 535\u2013543.","DOI":"10.1111\/j.1365-2559.2009.03423.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Pennanen M, Heiskanen I, Sane T, Rames S, Mustonen H, et al. (2015) Helsinki score\u2014a novel model for prediction of metastases in adrenocortical carcinomas. Hum Pathol 46: 404\u2013410.","DOI":"10.1016\/j.humpath.2014.11.015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, et al. (2022) Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol 33: 155\u2013196.","DOI":"10.1007\/s12022-022-09710-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, et al. (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179: G1\u2013G46.","DOI":"10.1530\/EJE-18-0608"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, et al. (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366: 2189\u20132197.","DOI":"10.1056\/NEJMoa1200966"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Debets P, Dreijerink KMA, Engelsman A, Dahele M, Haak HR, et al. (2024) Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study. Eur J Cancer 196: 113424.","DOI":"10.1016\/j.ejca.2023.113424"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Terzolo M, Fassnacht M, Perotti P, Lib\u00e9 A, Kastelan D, et al. (2023) Adjuvant mitotane <i>versus<\/i> surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 11: 720\u2013730.","DOI":"10.1016\/S2213-8587(23)00193-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Papathomas TG, Pucci E, Giordano TJ, Lu H, Duregon E, et al. (2016) An international Ki67 reproducibility study in adrenal cortical carcinoma. Am J Surg Pathol 40: 569\u2013576.","DOI":"10.1097\/PAS.0000000000000574"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Yamazaki Y, Nakamura Y, Shibahara Y, Konosu-Fukaya S, Sato N, et al. (2016) Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual <i>versus<\/i> digital image analysis. Hum Pathol 53: 41\u201350.","DOI":"10.1016\/j.humpath.2015.10.017"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, et al. (2021) S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol 186: 25\u201336.","DOI":"10.1530\/EJE-21-0510"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M, Jouinot A, Luscap W, et al. (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46: 607\u2013612.","DOI":"10.1038\/ng.2953"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Pozdeyev N, Fishbein L, Gay LM, Sokol ES, Hartmaier R, et al. (2021) Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr Relat Cancer 28: 671\u2013681.","DOI":"10.1530\/ERC-21-0040"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Ross JS, Wang K, Rand JV, Gay L, Presta MJ, et al. (2014) Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J Clin Pathol 67: 968\u2013973.","DOI":"10.1136\/jclinpath-2014-202514"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Vatrano S, Volante M, Duregon E, Giorcelli J, Izzo S, et al. (2018) Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. Mod Pathol 31: 1257\u20131269.","DOI":"10.1038\/s41379-018-0042-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, et al. (2015) Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab 100: E493\u2013E502.","DOI":"10.1210\/jc.2014-3282"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, et al. (2015) Genomic landscape of paediatric adrenocortical tumours. Nat Commun 6: 6302.","DOI":"10.1038\/ncomms7302"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27 Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, et al. (2016) Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29: 723\u2013736.","DOI":"10.1016\/j.ccell.2016.04.002"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, et al. (2018) Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab 103: 4511\u20134523.","DOI":"10.1210\/jc.2018-01348"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Lippert J, Altieri B, Morrison B, Steinhauer S, Smith G, et al. (2022) Prognostic role of targeted methylation analysis in paraffin-embedded samples of adrenocortical carcinoma. J Clin Endocrinol Metab 107: 2892\u20132899.","DOI":"10.1210\/clinem\/dgac470"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Nazha B, Zhuang TZ, Dada HI, Drusbosky LM, Brown JT, et al. (2022) Blood-based next-generation sequencing in adrenocortical carcinoma. Oncologist 27: 462\u2013468.","DOI":"10.1093\/oncolo\/oyac061"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Gara SK, Lack J, Zhang L, Harris E, Cam M, et al. (2018) Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nat Commun 9: 4172.","DOI":"10.1038\/s41467-018-06366-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, et al. (2017) Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol PO.17.00073.","DOI":"10.1200\/PO.17.00073"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, et al. (2013) Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 31: 3012\u20133018.","DOI":"10.1200\/JCO.2012.48.0988"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Grisanti S, Cosentini D, Sigala S, Berruti A (2022) Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. Curr Opin Oncol 34: 19\u201328.","DOI":"10.1097\/CCO.0000000000000799"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, et al. (2015) Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children\u2019s oncology group study. J Clin Oncol 33: 602\u2013609.","DOI":"10.1200\/JCO.2013.52.6863"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Rubinstein JC, Brown TC, Goh G, Juhlin CC, Stenman A, et al. (2016) Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma. Surgery 159: 296\u2013301.","DOI":"10.1016\/j.surg.2015.09.001"},{"key":"37","unstructured":"37 Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, et al. (2017) DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab 102: 923\u2013932."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Xiao H, He W, Chen P, Xu D, Zeng G, et al. (2019) Identification of seven aberrantly methylated and expressed genes in adrenocortical carcinoma. Front Endocrinol (Lausanne) 10: 472.","DOI":"10.3389\/fendo.2019.00472"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Mohan DR, Lerario AM, Else T, Mukherjee B, Almeida MQ, et al. (2019) Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin Cancer Res 25: 3276\u20133288.","DOI":"10.1158\/1078-0432.CCR-18-2693"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Cherradi N (2016) microRNAs as potential biomarkers in adrenocortical cancer: progress and challenges. Front Endocrinol (Lausanne) 6: 195.","DOI":"10.3389\/fendo.2015.00195"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Chehade M, Bullock M, Glover A, Hutvagner G, Sidhu S (2020) Key microRNA\u2019s and their targetome in adrenocortical cancer. Cancers (Basel) 12: 2198.","DOI":"10.3390\/cancers12082198"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Wang C, Sun Y, Wu H, Zhao D, Chen J (2014) Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology 64: 567\u2013576.","DOI":"10.1111\/his.12283"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Chabre O, Libe R, Assie G, Barreau O, Bertherat J, et al. (2013) Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer 20: 579\u2013594.","DOI":"10.1530\/ERC-13-0051"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, et al. (2009) miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 15: 7684\u20137692.","DOI":"10.1158\/1078-0432.CCR-09-1587"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E (2011) microRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117: 1630\u20131639.","DOI":"10.1002\/cncr.25724"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70: 4666\u20134675.","DOI":"10.1158\/0008-5472.CAN-09-3970"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Feinmesser M. Benbassat C, Meiri E, Benjamin H, Lebanony D, et al. (2015) Specific microrNAs differentiate adrenocortical adenomas from carcinomas and correlate with Weiss histopathologic system. Appl Immunohistochem Mol Morphol 23: 522\u2013531.","DOI":"10.1097\/PAI.0000000000000117"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 T\u00f6mb\u00f6l Z, Szab\u00f3 PM, Moln\u00e1r V, Wiener Z, T\u00f6lgyesi G, et al. (2009) Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 16: 895\u2013906.","DOI":"10.1677\/ERC-09-0096"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, et al. (2011) Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 64: 529\u2013535.","DOI":"10.1136\/jcp.2010.085621"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Duregon E, Rapa I, Votta A, Giorcelli J, Daffara F, et al. (2014) MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Hum Pathol 45: 1555\u20131562.","DOI":"10.1016\/j.humpath.2014.04.005"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, et al. (2009) Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15: 668\u2013676.","DOI":"10.1158\/1078-0432.CCR-08-1067"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 de Reyni\u00e8s A, Assi\u00e9 G, Rickman DS, Tissier F, Groussin L, et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108\u20131115.","DOI":"10.1200\/JCO.2008.18.5678"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Fragoso MCBV, Almeida MQ, Mazzuco TL, Mariani BMP, Brito LP, et al. (2012) Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 166: 61\u201367.","DOI":"10.1530\/EJE-11-0806"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Xiao H, Xu D, Chen P, Zeng G, Wang X, et al. (2018) Identification of five genes as a potential biomarker for predicting progress and prognosis in adrenocortical carcinoma. J Cancer 9: 4484\u20134495.","DOI":"10.7150\/jca.26698"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55 Sun-Zhang A, Juhlin CC, Carling T, Scholl U, Schott M, et al. (2024) Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival. ESMO Open 9: 103617.","DOI":"10.1016\/j.esmoop.2024.103617"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Jouinot A, Lippert J, Sibony M, Violon F, Jeanpierre L, et al. (2022) Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. Eur J Endocrinol 186: 607\u2013617.","DOI":"10.1530\/EJE-21-1228"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Nakamura Y, Yamazaki Y, Felizola SJ, Ise K, Morimoto R, et al. (2015) Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinol Metab Clin North Am 44: 399\u2013410.","DOI":"10.1016\/j.ecl.2015.02.007"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, et al. (2020) Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer 8: e000469.","DOI":"10.1136\/jitc-2019-000469"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Raj N, Zheng Y, Kelly V, Katz SS, Chou J, et al. (2020) PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol 38: 71\u201380.","DOI":"10.1200\/JCO.19.01586"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, et al. (2018) Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 6: 111.","DOI":"10.1186\/s40425-018-0424-9"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Habra MA, Stephen B, Campbell M, Hess K, Tapia C, et al. (2019) Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7: 253.","DOI":"10.1186\/s40425-019-0722-x"},{"key":"62","doi-asserted-by":"crossref","first-page":"1908771","DOI":"10.1080\/2162402X.2021.1908771","volume":"10","author":"O Klein","year":"2021","unstructured":"62 Klein O, Senko C, Carlino MS, Markman B, Jackett L, et al. (2021) Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. Oncoimmunology 10: 1908771.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Landwehr LS, Altieri B, Sbiera I, Remde H, Kircher S, et al. (2024) Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma. J Clin Endocrinol Metab 109: 2325\u20132334.","DOI":"10.1210\/clinem\/dgae109"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Zhang Z, Li M, Wang J, Liu M, Chen H, et al. (2022) Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma. Endocr Relat Cancer 29: 403\u2013413.","DOI":"10.1530\/ERC-22-0066"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Remde H, Schmidt-Pennington L, Reuter M, Landwehr LS, Jensen M, et al. (2023) Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur J Endocrinol 188: 485\u2013493.","DOI":"10.1093\/ejendo\/lvad054"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Karwacka I, Obo\u0142o\u0144czyk \u0141, Kaniuka-Jakubowska S, Sworczak K (2021) The role of immunotherapy in the treatment of adrenocortical carcinoma. Biomedicines 9: 98.","DOI":"10.3390\/biomedicines9020098"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Ababneh O, Ghazou A, Alawajneh M, Alhaj Mohammad S, Bani-Hani A, et al. (2024) The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: a systematic review and meta-analysis. Cancers (Basel) 16: 900.","DOI":"10.3390\/cancers16050900"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Wu K, Liu Z, Liang J, Zhu Y, Wang X, et al. (2023) Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma. Immunother Cancer 11: e007528.","DOI":"10.1136\/jitc-2023-007528"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Kitawaki Y, Nakamura Y, Kubota-Nakayama F, Yamazaki Y, Miki Y, et al. (2018) Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma. Hum Pathol 77: 88\u201397.","DOI":"10.1016\/j.humpath.2018.03.016"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 McHugh D, Gil J (2018) Senescence and aging: causes, consequences, and therapeutic avenues. J Cell Biol 217: 65\u201377.","DOI":"10.1083\/jcb.201708092"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Gonz\u00e1lez-Gualda E, Baker AG, Fruk L, Mu\u00f1oz-Esp\u00edn D (2021) A guide to assessing cellular senescence <i>in vitro<\/i> and <i>in vivo<\/i>. FEBS J 288: 56\u201380.","DOI":"10.1111\/febs.15570"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Malaise O, Paulissen G, Deroyer C, Ciregia F, Poulet C, et al. (2021) Influence of glucocorticoids on cellular senescence hallmarks in osteoarthritic fibroblast-like synoviocytes. J Clin Med 10: 5331.","DOI":"10.3390\/jcm10225331"},{"key":"73","doi-asserted-by":"publisher","unstructured":"73 Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, et al. (2019) Cellular senescence: defining a path forward. Cell 179: 813\u2013827.","DOI":"10.1016\/j.cell.2019.10.005"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Gao X, Yamazaki Y, Tezuka Y, Pieroni J, Ishii K, et al. (2020) Intratumoral heterogeneity of the tumor cells based on <i>in situ<\/i> cortisol excess in cortisol-producing adenomas; ~An association among morphometry, genotype and cellular senescence~. J Steroid Biochem Mol Biol 204: 105764.","DOI":"10.1016\/j.jsbmb.2020.105764"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/3\/72_EJ24-0466\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T03:23:30Z","timestamp":1741404210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/3\/72_EJ24-0466\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0466","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0466"}}